H.R. 1051 (119th)Congressional Activities
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Health|Drug safety, medical device, and laboratory regulationHealth
Current stageCommittee
Referred to the House Committee on Energy and Commerce.
Introduced
Committee
Floor
President
Law
Congressional Activities
This tab collects committee work, CRS research, hearings, and amendment activity as those sources become available for the bill.
No congressional activity records are linked to this bill yet.